James Race M.D.

Experienced Internal Medicine Physician with over 21 years as a principal investigator focused on improving patient adherence to treatment and managing chronic conditions. Strong communicator and leader with expertise in clinical trial oversight and regulatory compliance, ensuring effective patient outcomes and successful project collaboration.

• Active staff-Methodist Medical University
• Dept of Internal Medicines Teaching Council
• Former member Medical Executive Committee, ICU
• Committee, Emergency Services Committee, PCAR
• Chairman-Emergency Services Committee, Methodist Medical Center 2000-2002
• Active Staff- South Hampton Community Hospital Dallas
• Active Staff-Texas Specialty Hospital
• Active Staff-Vibra Specialty Hospital
• Medical Director-Manor Care Health Services Dallas
• Clinical Preceptor-UT Arlington Graduate Nurse Practitioner Program
• Clinical Preceptor-Texas Women's University Graduate Nurse Practitioner Program
• Former member-Admissions Committee, UTSW Medical School
• Past Chairman-Dallas Division American Heart Association (AHA)
• Member-Executive Board AHA, Dallas Division
• Chairman AHA Minority Council
• Past Chairman AHA Community Site
• Member-Dallas County Medical Society Board of Directors (1997-1999)
• Dallas County Public Health Planning Committee (1999-2000)
• Delegate to Texas Medical Association
• Member-TEXPAC Board of Directors (1999-2000)
• General Internal Medicine Statewide Preceptorship Program
• Past President-CV Roman Medical Society
• Project Director-Robert Wood Johnson Foundation Grant
• Reach Out: Physician's Initiative to Expand Health Care to Underserved Americans
• Speaker's Bureau-AHA
• Speaker's Bureau-Methodist Medical Center Senior Access Program
• Chairman of Physicians Advisory Board for Dallas Heart Disease Prevention Program
• Cooper Institute Community Advisory Board (2001-present)
• Second VP-Dallas Division AHA (2000)
• President-Dallas Division AHA (2002-2003)
• Medical Consultant-KTVT Channel 11 News
• Dallas County Medical Society
• Texas Medical Association
• Texas Medical Directors Association
• Texas Geriatric Society

• Internal Medicine, Western Reserve Care System
• Northeastern Ohio University College of Medicine
• Youngstown, OH
• 01 July 1984-30 June 1987
• Chief Resident-Dept of Internal Medicine WRCS
• 01 July 1987- 30 June 1988

• AHA Pastor's Brunch Why We Die 01 Feb 2002
• Methodist Medical Center (Dallas) Senior Access Program
• Heart Disease 20 Feb 2002
• Black Inventors & Leaders Conference Cathedral Faith Baptist Church 24 Feb 2002

• Double Blind, Placebo controlled, Randomized study of efficacy & tolerability of XXX and YYY in relieving symptoms of OA of the knee 2002
• Phase III, Open Label study to examine the long term effect on glucose control and the safety and tolerability of XXX given twice daily to subjects with type 2 DM 2002-2003
• Impact of Point of Care versus Laboratory Testing of HbA1C & Intense vs. Standard Monitoring of Titration Algorithm with XXX 2002-2003
• Phase III, Multinational, Multi-center trial to Compare the effects of XXX/YYY to YYY and ZZZ combined on the Reduction of Cardiovascular Morbidity and Mortality in patients with High Risk HTN 2004
• Phase 2b, Multi-center, Randomized, Double blind, Placebo-controlled, parallel group dose ranging study of XXX in subjects with functional Dyspepsia 2004
• Effects of XXX on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with low bone density 2004
• A Phase II, Double Blind, Randomized Placebo controlled, Proof of concept Study of the Efficacy, Safety and Tolerability of XXX in Combination with YYY in subjects with type II Diabetes 2004
• Effect of XXX in Combination with Fixed-dose YYY Therapy on Systolic Blood Pressure in Hypertensive patients 2005
• Randomized, Double Blind Trial of 2 doses of XXX compared to Placebo with acute, painful Musculoskeletal Spams of the lower back 2005
• A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose XXX Monotherapy (80mg) in Managing Patients with HTN 2005
• A 4 week Dose Ranging study to evaluate Anti-Dyslipidemic effects, other pharmacodynamics effects, safety, and tolerability of XXX with concomitant open label simvastatin therapy in patients with elevated triglycerides, elevated low density lipid cholesterol and abdominal obesity: a Randomized, double blind, Placebo Controlled, Multi-Center, Parallel Group study with Fenofibrate as reference treatment 2006
• Phase III, A Multi-Center, Randomized, Double Blind, Placebo-controlled study to Determine the Efficacy and Safety of the Combination of XXX and YYY, in Subjects with Type 2 DM 2006
• Phase III, A Multi-Center, Randomized, Open-Label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 weeks of treatment with XXX to YYY as Add-on Therapy in Patients with Type 2 DM Inadequately Controlled with ZZZ Monotherapy in a Community-Based Practice Setting 2007
• Phase III, a long term, open label extension study to investigate the long term safety of XXX in subjects with Type 2 DM 2007
• Randomized, Double Blind trial of the combination of XXX and YYY compared to placebo and either product alone in patients with acute, painful musculoskeletal spasm of lower back 2007
• Phase III, A Rapid onset and short duration XXX in combination with YYY versus YYY alone in patients with Type 2 DM: A Randomized, Double Blind, Placebo controlled trial for 6 months 2007
• Phase III, A Multi-center Randomized, Double Blind, Placebo-controlled study to determine the Efficacy and Safety of XXX When used in Combination with YYY in subject with Type 2 DM 2007
• Phase III, Randomized, Double Blind, Placebo-controlled study to evaluate the Efficacy and Safety in Black subjects with essential HTN 2008
• Phase III, A Multi-center Randomized, Double Blind, Placebo-Active-controlled study to evaluate the Durability of the efficacy and safety of XXX compared to YYY when used in combination with ZZZ in subjects with type 2 DM 2009
• Phase III, A Multi-center Randomized, Double Blind, Placebo-controlled study of the efficacy and safety of XXX for the Prophylaxis of Gout Flares during the initiation of YYY therapy 2009
• Phase III, A Randomized, Double Blind, Placebo-controlled Parallel group, Multi-center study to determine the efficacy and safety of 2 dose levels of XXX compared with Placebo in subjects with Type II DM 2009
• Phase III, A Randomized, Open Label, Parallel group, Multi-center study to determine the efficacy and long-term safety of XXX Compared with YYY in Subjects with Type 2 DM 2009
• Phase III, A Randomized, Double Blind, Placebo-controlled Parallel group, Multi-center study to determine the efficacy and safety of XXX when used in combination with YYY with or without ZZZ in subjects with type 2 DM 2009
• Phase III, A Randomized, Double Blind, Placebo controlled, Parallel group, Multi-center study to determine the efficacy of XXX in combination with YYY and ZZZ compared with YYY Plus ZZZ and Placebo and WWW 2009
• Phase III, A Randomized, Open Label, Parallel group, Multi-center study to determine the efficacy off XXX in hypertensive subjects. 2009
• Phase III, A Multi-center Randomized, Double Blind, Placebo-Active-controlled study to determine the efficacy and safety of XXX when used in combination with YYY plus ZZZ, YYY plus UUU and YYY Plus Placebo in subjects with Type 2 DM 2009
• Phase III, A Randomized, Open Label, Multi-center Placebo-Active-controlled Parallel group study to determine the safety and efficacy of XXX administered in combination with YYY as compared with combination of YYY and ZZZ in subjects with Type 2 DM 2009
• YYY and ZZZ compared with YYY plus ZZZ and Placebo and with YYY Plus ZZZ and WWW. 2009
• Phase III, A Randomized, Double-blind, Placebo-and Active-controlled, Parallel-group, Multi-center study to determine the Efficacy and safety of XXX when used in combination with YYY plus ZZZ, YYY Plus UUU and YYY plus Placebo in subjects with Type II Diabetes Mellitus. 2009
• Phase III, A Randomized, Open Label, Active-controlled, Parallel group, Multi-center study to determine the Efficacy and safety of XXX Administered in Combination with YYY as compared with Combination of YYY and ZZZ in Subjects with Type II Diabetes Mellitus. 2009
• Phase II, A Randomized, Double-blind, Placebo-and Active-controlled, Parallel-group, Multi-center study to determine the Efficacy and safety of XXX when used in combination with YYY and ZZZ plus Placebo in subjects with Type II Diabetes Mellitus 2011
• Phase III, Randomized, Double Blind, Placebo controlled, Parallel Group, Multi-center in OAB subjects to confirm the efficacy of XXX compared to YYY 2011
• Phase III, Randomized, Double Blind, Placebo-controlled study to evaluate the efficacy and safety of XXX in treatment of patients with Diarrhea-Predominant IBS. 2011
• Phase III, A Randomized Double-blind, Placebo-controlled Parallel group, Multi-center study to evaluate the Efficacy, Safety and Tolerability of XXX in patients with Constipation symptoms. 2012
• Phase III, A study to assess treatment efficacy and safety of XXX in subjects with Constipation along with symptoms of IBS. 2012
• Phase III, A Randomized Double-blind clinical trial to study efficacy and safety of XXX a fixed combination of YYY for treatment of patients with Type 2 DM with inadequate Glycemic control on XXX. 2013
• A study to assess repeat treatment efficacy and safety of XXX in subjects with IBS and Diarrhea. 2013
• A Randomized, Double Blind, Placebo controlled, Multi-center study to assess cardiovascular outcomes following treatment with XXX in subjects with Type 2 DM. 2013
• A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center study to evaluate the blood pressure reduction with ambulatory blood pressure monitoring (ABPM) safety and tolerability of XXX in the treatment of subjects with HTN and Type 2 DM. 2014
• A National, Randomized, 12wk Double Blind, Placebo-controlled Study to assess the safety and efficacy of XXX in patients with Chronic Idiopathic Constipation. 2014
• Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of XXX Injection in Patients with Nephropathy Due to Diabetes. 2015
• Phase III, A study to assess treatment efficacy and safety of XXX in subjects with Constipation and diarrhea. 2015
• Phase III, A Multi-center Randomized, Double Blind, Placebo-controlled study to determine the Efficacy and Safety of XXX When used in Combination with YYY in female subjects with frequent Candidal infections 2016
• Randomized, Double Blind trial of the combination of XXX and YYY compared to placebo in patients with acute STIs 2016
• Phase III, A Randomized, Open Label, Parallel group, Multi-center study to determine the efficacy off XXX in COPD patients 2017
• Phase III, a long term, open label extension study to investigate the long term safety of XXX in Female subjects with OAB 2017
• Phase III, Double Blind, Placebo controlled, Parallel Group, Multi-center in asthmatic patients confirm the efficacy of XXX compared to YYY 2018
• Phase II, 5 year Diabetic trial with Merck 2019- 2024
• Phase II, COVID trial 2020- 2021
• Phase II, Device trial for GERD 2021-2024
• Phase II, Pharmacodynamic Study to Evaluate the Therapeutic Equivalence of Tiotropium Bromide Inhalation Powder to Reference (Tiotropium Bromide Inhalation Powder) in Subjects with COPD 2019-2021
• Phase 3, Eli Lilly Trial. Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events. 2023- Currently ongoing